According to CRISPR Therapeutics's latest financial reports the company has a price-to-book ratio of 2.43.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Year | P/B ratio | Change |
---|---|---|
2023-12-31 | 2.64 | 55.63% |
2022-12-31 | 1.70 | -29.79% |
2021-12-31 | 2.42 | -63.11% |
2020-12-31 | 6.55 | 66.24% |
2019-12-31 | 3.94 | 4.33% |
2018-12-31 | 3.78 | -24.93% |
2017-12-31 | 5.03 | 45.27% |
2016-12-31 | 3.46 | |
2015-12-31 | N/A |
Company | P/B ratio | differencediff. | Country |
---|---|---|---|
ORIC Pharmaceuticals
ORIC | 2.43 | 0.02% | ๐บ๐ธ USA |